Analysts take a look at Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) having this to say.

May 24, 2018 - By Vivian Park

Investors sentiment decreased to 1.17 in 2017 Q4. Its down 0.26, from 1.43 in 2017Q3. It turned negative, as 19 investors sold Vanda Pharmaceuticals Inc. shares while 34 reduced holdings. 16 funds opened positions while 46 raised stakes. 39.77 million shares or 2.28% more from 38.89 million shares in 2017Q3 were reported.
3,475 were reported by Meeder Asset Inc. Parametric Portfolio Associates Limited Liability Corporation reported 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Ajo Limited Partnership holds 398,347 shares or 0.03% of its portfolio. Moreover, Voya Inv Mngmt Lc has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 20,118 shares. Clarivest Asset Management Ltd, California-based fund reported 45,999 shares. Tiaa Cref Inv Mngmt Ltd Liability Com invested 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Royal Commercial Bank Of Canada holds 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 3,880 shares. Rice Hall James And Assoc Lc accumulated 0.02% or 28,245 shares. Geode Capital Limited Liability Corporation has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). 277,088 were reported by Sei Investments. Balyasny Asset Mgmt Lc has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Baker Bros Advsr Limited Partnership holds 0.06% or 423,884 shares in its portfolio. Hbk Invs Ltd Partnership reported 0.01% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Rothschild Asset Mngmt has 1.37M shares for 0.22% of their portfolio. Dupont Mgmt Corp invested in 0.03% or 73,870 shares.

Since January 2, 2018, it had 0 insider purchases, and 8 selling transactions for $4.89 million activity. $159,605 worth of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) was sold by Birznieks Gunther on Wednesday, February 28. On Tuesday, January 2 Kelly James Patrick sold $140,494 worth of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) or 9,155 shares. $1.14 million worth of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) was sold by Polymeropoulos Mihael Hristos on Wednesday, February 28.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Among 4 analysts covering Vanda (NASDAQ:VNDA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda had 6 analyst reports since January 8, 2018 according to SRatingsIntel. The rating was maintained by Oppenheimer with “Buy” on Monday, March 5. As per Tuesday, February 13, the company rating was maintained by Jefferies. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has “Buy” rating given on Wednesday, February 28 by Seaport Global. As per Monday, January 8, the company rating was maintained by Oppenheimer. Below is a list of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) latest ratings and price target changes.

23/05/2018 Broker: Citigroup Rating: Buy Initiates Coverage On
05/03/2018 Broker: Oppenheimer Rating: Buy New Target: $27.0 Maintain
28/02/2018 Broker: Seaport Global Rating: Buy New Target: $21.0 Maintain
13/02/2018 Broker: Jefferies Rating: Buy New Target: $20.0 Maintain
19/01/2018 Broker: Seaport Global Rating: Buy New Target: $20 Initiates Coverage On
08/01/2018 Broker: Oppenheimer Rating: Buy Maintain

The stock increased 1.63% or $0.27 during the last trading session, reaching $17.17. About 176,344 shares traded. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 15.63% since May 24, 2017 and is uptrending. It has outperformed by 4.08% the S&P500.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $895.00 million. The companyÂ’s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It currently has negative earnings. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

More important recent Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on May 23, 2018, also Seekingalpha.com published article titled: “Vanda’s Hetlioz effective in jet lag study”, Seekingalpha.com published: “Vanda Pharmaceuticals’ (VNDA) CEO Mihael Polymeropoulos on Q1 2018 Results – Earnings Call Transcript” on May 03, 2018. More interesting news about Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) was released by: Gurufocus.com and their article: “HETLIOZ® (tasimelteon) Effective in Treating Jet Lag during Transatlantic Travel” with publication date: May 23, 2018.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: